WS6

WS6 is an IkB kinase and EBP1 inhibitor, with IC50 values of 0.24 nM, 0.21 nM, and 40.48 nM in MV4-11, MOLM13, and K562 cells, respectively. WS6 promotes the proliferation of alpha and beta cells in the pancreas, has antioxidant and anti-inflammatory activities, and can alleviate depression like behavior in rats[1][2][4].

Product Specifications

CAS Number

1421227-53-3

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

EGFR; FLT3; GABA Receptor; IKK; PI3K

Type

Reference compound

Related Pathways

JAK/STAT Signaling; Membrane Transporter/Ion Channel; Neuronal Signaling; NF-κB; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK

Applications

COVID-19-immunoregulation

Field of Research

Metabolic Disease; Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/WS6.html

Purity

99.94

Solubility

DMSO : ≥ 100 mg/mL

Smiles

O=C(NC1=CC=C(CN2CCN(C)CC2)C(C(F)(F)F)=C1)CC3=CC=C(OC4=NC=NC(NC(C5CC5)=O)=C4)C=C3

Molecular Formula

C29H31F3N6O3

Molecular Weight

568.59

Precautions

H302, H315, H319, H335

References & Citations

[1]Boerner BP, George NM, Mir SU, Sarvetnick NE. WS6 induces both alpha and beta cell proliferation without affecting differentiation or viability. Endocr J. 2015;62 (4) :379-86. |[2]Zhang H, et al. WS6 Induces Adult Hippocampal Neurogenesis in Correlation to its Antidepressant Effect on the Alleviation of Depressive-like Behaviors of Rats. Neuroscience. 2021 Oct 1;473:119-129.|[3]Massudi H, et al. Inhibitors of the Oncogenic PA2G4-MYCN Protein-Protein Interface. Cancers (Basel) . 2023 Mar 17;15 (6) :1822. |[4]Bregante J, et al. Efficacy and Synergy of Small Molecule Inhibitors Targeting FLT3-ITD+ Acute Myeloid Leukemia. Cancers (Basel) . 2021 Dec 8;13 (24) :6181. |[5]Zhang J, et al. ERBB2 signaling drives supporting cell proliferation in vitro and apparent supernumerary hair cell formation in vivo in the neonatal mouse cochlea. Eur J Neurosci. 2018 Nov;48 (10) :3299-3316. |[6]Firdoos S, et al. In silico identification of novel stilbenes analogs for potential multi-targeted drugs against Alzheimer's disease. J Mol Model. 2023 Jun 14;29 (7) :209.